PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
FRLN vs. SPHY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between FRLN and SPHY is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

FRLN vs. SPHY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Freeline Therapeutics Holdings plc (FRLN) and SPDR Portfolio High Yield Bond ETF (SPHY). The values are adjusted to include any dividend payments, if applicable.

0.00%1.00%2.00%3.00%4.00%SeptemberOctoberNovemberDecember2025February0
4.16%
FRLN
SPHY

Key characteristics

Returns By Period


FRLN

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

SPHY

YTD

1.85%

1M

0.77%

6M

4.03%

1Y

10.18%

5Y*

4.45%

10Y*

4.59%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

FRLN vs. SPHY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FRLN

SPHY
The Risk-Adjusted Performance Rank of SPHY is 9393
Overall Rank
The Sharpe Ratio Rank of SPHY is 9393
Sharpe Ratio Rank
The Sortino Ratio Rank of SPHY is 9494
Sortino Ratio Rank
The Omega Ratio Rank of SPHY is 9292
Omega Ratio Rank
The Calmar Ratio Rank of SPHY is 9393
Calmar Ratio Rank
The Martin Ratio Rank of SPHY is 9393
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

FRLN vs. SPHY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Freeline Therapeutics Holdings plc (FRLN) and SPDR Portfolio High Yield Bond ETF (SPHY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
No data
The chart of Calmar ratio for FRLN, currently valued at 0.00, compared to the broader market0.002.004.006.000.004.43
FRLN
SPHY


Rolling 12-month Sharpe Ratio0.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
1.00
2.57
FRLN
SPHY

Dividends

FRLN vs. SPHY - Dividend Comparison

FRLN has not paid dividends to shareholders, while SPHY's dividend yield for the trailing twelve months is around 7.68%.


TTM20242023202220212020201920182017201620152014
FRLN
Freeline Therapeutics Holdings plc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
SPHY
SPDR Portfolio High Yield Bond ETF
7.68%7.80%7.30%6.46%5.13%5.63%5.73%4.09%4.41%4.28%4.29%3.98%

Drawdowns

FRLN vs. SPHY - Drawdown Comparison


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-97.64%
0
FRLN
SPHY

Volatility

FRLN vs. SPHY - Volatility Comparison

The current volatility for Freeline Therapeutics Holdings plc (FRLN) is 0.00%, while SPDR Portfolio High Yield Bond ETF (SPHY) has a volatility of 0.84%. This indicates that FRLN experiences smaller price fluctuations and is considered to be less risky than SPHY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%0.50%1.00%1.50%SeptemberOctoberNovemberDecember2025February0
0.84%
FRLN
SPHY
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab